These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 22117148)

  • 1. Sunitinib for advanced pancreatic neuroendocrine tumors.
    Hubner RA; Valle JW
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1817-27. PubMed ID: 22117148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
    Bisht S; Feldmann G; Brossart P
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):777-88. PubMed ID: 23590356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
    Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
    J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors.
    Spiegel AM; Libutti SK
    Nat Rev Clin Oncol; 2011 May; 8(5):258-9. PubMed ID: 21448150
    [No Abstract]   [Full Text] [Related]  

  • 5. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib in pancreatic neuroendocrine tumors.
    Raymond E; Hammel P; Dreyer C; Maatescu C; Hentic O; Ruszniewski P; Faivre S
    Target Oncol; 2012 Jun; 7(2):117-25. PubMed ID: 22661319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
    Capdevila J; Tabernero J
    Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
    Mateo J; Heymach JV; Zurita AJ
    Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome.
    Wang W; Jiang CY; Wang HW
    J Clin Gastroenterol; 2015 Jan; 49(1):89-90. PubMed ID: 24921213
    [No Abstract]   [Full Text] [Related]  

  • 11. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
    J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
    Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
    Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors.
    Deeks ED; Raymond E
    BioDrugs; 2011 Oct; 25(5):307-16. PubMed ID: 21942915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
    Raymond E; Ruszniewski P
    Target Oncol; 2012 Jun; 7(2):91-2. PubMed ID: 22669625
    [No Abstract]   [Full Text] [Related]  

  • 15. Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.
    Vinik A; Bottomley A; Korytowsky B; Bang YJ; Raoul JL; Valle JW; Metrakos P; Hörsch D; Mundayat R; Reisman A; Wang Z; Chao RC; Raymond E
    Target Oncol; 2016 Dec; 11(6):815-824. PubMed ID: 27924459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.
    Rinzivillo M; Fazio N; Pusceddu S; Spallanzani A; Ibrahim T; Campana D; Marconcini R; Partelli S; Badalamenti G; Brizzi MP; Catena L; Schinzari G; Carnaghi C; Berardi R; Faggiano A; Antonuzzo L; Spada F; Gritti S; Femia D; Gelsomino F; Bongiovanni A; Ricci S; Brighi N; Falconi M; Delle Fave G; Panzuto F
    Pancreatology; 2018 Mar; 18(2):198-203. PubMed ID: 29361429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L; Schwarz RE
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
    Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S
    Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms.
    Crippa S; Partelli S; Boninsegna L; Falconi M
    Ann Oncol; 2012 Jul; 23(7):1928. PubMed ID: 22753260
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe perirenal hematoma in a patient with a single kidney treated with sunitinib for metastatic pancreatic neuroendocrine tumor.
    Zugazagoitia J; Sastre J; Barrera J; García B; Díaz-Rubio E
    J Cancer Res Ther; 2012; 8(2):303-5. PubMed ID: 22842382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.